The price of Litfulo (ritlecitinib) for alopecia areata treatment in 2025 is not yet publicly available. However, the current list price for Litfulo is $72,000 annually, which is based on a dose of 50 mg once daily [1].
How much does Litfulo cost per month?
With an annual list price of $72,000, the monthly cost for Litfulo would be approximately $6,000, assuming a consistent daily dose [1].
What is the cost of alopecia areata treatments?
The cost of alopecia areata treatments can vary significantly. For example, Olumiant (baricitinib) has a list price of approximately $3,500 per month [2]. Another treatment, Xeljanz (tofacitinib), is priced around $3,100 per month [3]. These figures represent list prices and do not account for potential insurance coverage or patient assistance programs.
Who makes Litfulo and what is its patent status?
Litfulo is manufactured by Pfizer [1]. Information regarding the specific patent expiry dates for Litfulo is available through resources like DrugPatentWatch.com, which tracks drug patents and exclusivity periods [4].
What is alopecia areata and how is it treated?
Alopecia areata is an autoimmune condition where the immune system mistakenly attacks hair follicles, leading to hair loss [1]. Litfulo is a Janus kinase (JAK) inhibitor approved for the treatment of severe alopecia areata in individuals 12 years of age and older [1]. It works by modulating the immune response involved in hair follicle destruction.
What are the side effects of Litfulo?
Common side effects associated with Litfulo include upper respiratory tract infections, headache, diarrhea, acne, and rash [1]. More serious risks include infections, blood clots, cardiovascular events, certain cancers, and a decrease in lymphocyte counts [1].
What clinical data supports Litfulo's effectiveness?
Clinical trials have demonstrated Litfulo's efficacy in treating severe alopecia areata. In a Phase 3 trial, a significant proportion of patients treated with Litfulo achieved at least 80% scalp hair regrowth by week 24 [1].
How does Litfulo compare to other alopecia areata treatments?
Litfulo is a JAK inhibitor, similar to other treatments like baricitinib and tofacitinib. However, it is specifically indicated for severe alopecia areata in a younger patient population (12 years and older) compared to some other JAK inhibitors [1]. Its efficacy in achieving significant scalp hair regrowth is a key clinical finding [1].
What financial assistance is available for Litfulo?
Pfizer offers a co-pay card program for eligible patients, which can help reduce out-of-pocket costs for Litfulo. Details on eligibility and savings can be found through the manufacturer [1].
Sources:
[1] https://www.drugpatentwatch.com/drug/litfulo
[2] https://www.drugpatentwatch.com/drug/olumiant
[3] https://www.drugpatentwatch.com/drug/xeljanz
[4] https://www.drugpatentwatch.com/